Investors sold shares of Boston Scientific Corp. (NYSE:BSX) on strength during trading hours on Thursday. $19.61 million flowed into the stock on the tick-up and $41.46 million flowed out of the stock on the tick-down, for a money net flow of $21.85 million out of the stock. Of all stocks tracked, Boston Scientific Corp. had the 0th highest net out-flow for the day. Boston Scientific Corp. traded up $0.15 for the day and closed at $23.78

A number of brokerages recently issued reports on BSX. Evercore ISI boosted their target price on shares of Boston Scientific Corp. from $21.50 to $23.50 and gave the stock a “buy” rating in a research report on Wednesday, April 27th. Wedbush boosted their target price on shares of Boston Scientific Corp. from $19.00 to $23.00 and gave the stock a “neutral” rating in a research report on Thursday, April 28th. TheStreet raised shares of Boston Scientific Corp. from a “hold” rating to a “buy” rating in a research report on Wednesday, April 27th. Longbow Research began coverage on shares of Boston Scientific Corp. in a research report on Friday, March 18th. They set a “buy” rating on the stock. Finally, Piper Jaffray Cos. reaffirmed an “overweight” rating and set a $26.00 target price on shares of Boston Scientific Corp. in a research report on Wednesday, May 25th. Four investment analysts have rated the stock with a hold rating and twenty-one have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of $23.49.

The stock’s market cap is $32.27 billion. The firm’s 50 day moving average price is $23.00 and its 200 day moving average price is $19.88.

Boston Scientific Corp. (NYSE:BSX) last released its quarterly earnings data on Wednesday, April 27th. The company reported $0.28 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.24 by $0.04. During the same quarter in the prior year, the firm earned $0.21 EPS. The firm had revenue of $1.96 billion for the quarter, compared to the consensus estimate of $1.91 billion. The company’s revenue was up 11.1% compared to the same quarter last year. Analysts predict that Boston Scientific Corp. will post $1.09 earnings per share for the current fiscal year.

In other news, EVP Timothy A. Pratt sold 39,927 shares of the business’s stock in a transaction that occurred on Wednesday, April 27th. The stock was sold at an average price of $21.40, for a total transaction of $854,437.80. Following the completion of the sale, the executive vice president now owns 291,724 shares in the company, valued at $6,242,893.60. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, SVP Kevin J. Ballinger sold 111,807 shares of the business’s stock in a transaction that occurred on Wednesday, April 27th. The shares were sold at an average price of $21.62, for a total value of $2,417,267.34. Following the sale, the senior vice president now owns 83,600 shares of the company’s stock, valued at approximately $1,807,432. The disclosure for this sale can be found here.

A number of large investors recently made changes to their positions in the company. Tributary Capital Management LLC increased its stake in shares of Boston Scientific Corp. by 36.9% in the fourth quarter. Tributary Capital Management LLC now owns 134,730 shares of the company’s stock valued at $2,484,000 after buying an additional 36,330 shares during the period. GSA Capital Partners LLP bought a new stake in shares of Boston Scientific Corp. during the fourth quarter valued at about $1,976,000. Mizuho Trust & Banking Co. Ltd. increased its stake in shares of Boston Scientific Corp. by 3.4% in the fourth quarter. Mizuho Trust & Banking Co. Ltd. now owns 2,080,627 shares of the company’s stock valued at $38,720,000 after buying an additional 67,512 shares during the period. GAM Holding AG increased its stake in shares of Boston Scientific Corp. by 4.8% in the fourth quarter. GAM Holding AG now owns 269,234 shares of the company’s stock valued at $4,965,000 after buying an additional 12,210 shares during the period. Finally, Vanguard Group Inc. increased its stake in shares of Boston Scientific Corp. by 3.0% in the fourth quarter. Vanguard Group Inc. now owns 94,937,112 shares of the company’s stock valued at $1,750,640,000 after buying an additional 2,753,185 shares during the period.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.